| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.1 | 3.1 |
| Profit before tax | -46.5 | -17.5 |
| Net income | -46.5 | -17.5 |
| EPS (diluted, $ a share) | $-0.46 | $-0.25 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -63.1% |
|---|
10-Q filed with the SEC, NASDAQ: IRD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Opus Genetics, Inc.: key numbers
- Share price
- $4.04Close, Nov 16
- Market cap
- $390M
- Shares outstanding
- 96.65MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Opus Genetics, Inc.
All →Opus Genetics Financial Results
Opus Genetics reported financial results for the third quarter of 2026, highlighting a cash runway extending into 2029. The company achieved several clinical milestones, including full enrollment of its OPGx-LCA5 Phase 3 trial and FDA clearance of the IND for OPGx-RDH12. Additionally, the FDA approval of RYZUMVI for presbyopia triggered a regulatory milestone payment to the company.
- Term
- Q3 2026
“The last several months have marked a period of tremendous advancement for our leading gene therapy programs. Positive Cohort 1 data from our Phase 1/2 trial of OPGx-BEST1 provide important evidence of its potential to improve both visual function and retinal structure in patients with BEST1-related retinal disease.”
George Magrath, M.D., Chief Executive Officer of Opus Genetics
“The FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia marks the second FDA-approved indication for RYZUMVI®, demonstrating the capabilities of our clinical and regulatory teams. With our cash runway into 2029, we remain focused on bringing potentially transformative gene therapies to patients with rare inherited retinal diseases.”
George Magrath, M.D., Chief Executive Officer of Opus Genetics
Opus Genetics CEO George Magrath Sells $110K of Stock
George Magrath, CEO, sold 28,258 shares of Opus Genetics, Inc. at $3.90 a share, worth $110K in total on Nov 3, 2026. Shares held after the trade: 2,010,636 (-1.4%).
- Value
- $110K
- Shares
- 28,258
- Price
- $3.90
- Role
- CEO
- Holding change
- -1.4%
- Trade date
- Nov 3, 2026
Opus Genetics COO Joseph K. Schachle Sells $17K of Stock
Joseph K. Schachle, COO, sold 4,767 shares of Opus Genetics, Inc. at $3.56 a share, worth $17K in total on Oct 23, 2026. Shares held after the trade: 286,673 (-1.6%).
- Value
- $17K
- Shares
- 4,767
- Price
- $3.56
- Role
- COO
- Holding change
- -1.6%
- Trade date
- Oct 23, 2026
Opus Genetics President Benjamin R. Yerxa Sells $117K of Stock
Benjamin R. Yerxa, President, sold 33,189 shares of Opus Genetics, Inc. at $3.53 to $3.55 a share (average $3.54) in 2 transactions, worth $117K in total on Oct 23, 2026. Shares held after the trade: 670,917 (-3.7%).
- Value
- $117K
- Shares
- 33,189
- Average price
- $3.54
- Role
- President
- Holding change
- -3.7%
- Trade date
- Oct 23, 2026
Opus Genetics CFO Robert E. Gagnon Sells $49.6K of Stock
Robert E. Gagnon, CFO, sold 14,000 shares of Opus Genetics, Inc. at $3.55 a share, worth $49.6K in total on Oct 23, 2026. Shares held after the trade: 542,375 (-2.5%).
- Value
- $49.6K
- Shares
- 14,000
- Price
- $3.55
- Role
- CFO
- Holding change
- -2.5%
- Trade date
- Oct 23, 2026
Opus Genetics CEO George Magrath Sells $34.4K of Stock
George Magrath, CEO, sold 9,591 shares of Opus Genetics, Inc. at $3.58 a share, worth $34.4K in total on Oct 23, 2026. Shares held after the trade: 2,038,894 (-0.5%).
- Value
- $34.4K
- Shares
- 9,591
- Price
- $3.58
- Role
- CEO
- Holding change
- -0.5%
- Trade date
- Oct 23, 2026